34 related articles for article (PubMed ID: 24171960)
1. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].
Zhang L; Li YL; Liu YM; Liu YB; Shang BJ; Cheng W; Dong XY; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):57-62. PubMed ID: 38178769
[No Abstract] [Full Text] [Related]
2. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
[TBL] [Abstract][Full Text] [Related]
3. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
[TBL] [Abstract][Full Text] [Related]
4. Del(1p32): prime time in (ultra) high-risk myeloma.
Khot A
Blood; 2023 Mar; 141(11):1241-1243. PubMed ID: 36929439
[No Abstract] [Full Text] [Related]
5. del(1p32), a powerful prognostic factor in myeloma.
Blood; 2023 Mar; 141(11):1367. PubMed ID: 36929429
[No Abstract] [Full Text] [Related]
6. Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma.
Møller HEH; Preiss BS; Pedersen P; Østergaard B; Frederiksen M; Abildgaard N; Møller MB
Eur J Haematol; 2018 Jul; ():. PubMed ID: 29999206
[TBL] [Abstract][Full Text] [Related]
7. Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma.
Li F; Hu L; Xu Y; Li Z; Yi S; Gu Z; Li C; Hao M; Ru K; Zhan F; Zetterberg A; Yuan W; Cheng T; Qiu L
Leukemia; 2016 May; 30(5):1197-201. PubMed ID: 26460211
[No Abstract] [Full Text] [Related]
8. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
9. Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.
Wang L; Cui J; Liu L; Sheng Z
Hematol Oncol; 2012 Dec; 30(4):163-9. PubMed ID: 22189704
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
Li F; Xu Y; An G; Hu LP; Zhang YR; Li ZJ; Yuan WP; Cheng T; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):862-7. PubMed ID: 24171960
[TBL] [Abstract][Full Text] [Related]
11. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
Chang H; Ning Y; Qi X; Yeung J; Xu W
Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
14. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]